Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
Aranda E, Viéitez JM, Gómez-España A, Gil Calle S, Salud-Salvia A, Graña B, Garcia-Alfonso P, Rivera F, Quintero-Aldana GA, Reina-Zoilo JJ, González-Flores E, Salgado Fernández M, Guillén-Ponce C, Garcia-Carbonero R, Safont MJ, La Casta Munoa A, García-Paredes B, López López R, Sastre J, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Aranda E, et al. Among authors: gil calle s. ESMO Open. 2020 Nov;5(6):e000944. doi: 10.1136/esmoopen-2020-000944. ESMO Open. 2020. PMID: 33148620 Free PMC article. Clinical Trial.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Sastre J, et al. ESMO Open. 2021 Apr;6(2):100062. doi: 10.1016/j.esmoop.2021.100062. Epub 2021 Mar 10. ESMO Open. 2021. PMID: 33711671 Free PMC article. Clinical Trial.
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, Massutí B, Aparicio J, Dueñas R, González-Flores E, Carrato A, Marcuello E, Gómez A, Cabrera E, Queralt B, Gómez MJ, Guasch I, Etxeberría A, Alfaro J, Campos JM, Reina JJ, Aranda E. Benavides M, et al. Among authors: gil calle s. Clin Colorectal Cancer. 2012 Sep;11(3):200-6. doi: 10.1016/j.clcc.2012.01.003. Epub 2012 Mar 14. Clin Colorectal Cancer. 2012. PMID: 22421001 Clinical Trial.
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Benavides M, Alcaide-Garcia J, Torres E, Gil-Calle S, Sevilla I, Wolman R, Durán G, Álvarez M, Reyna-Fortes C, Ales I, Pereda T, Robles M, Kushnir M, Odegaard J, Faull I, Alba E. Benavides M, et al. Among authors: gil calle s. ESMO Open. 2022 Jun;7(3):100481. doi: 10.1016/j.esmoop.2022.100481. Epub 2022 May 4. ESMO Open. 2022. PMID: 35525184 Free PMC article.
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limón ML, Garcia-Carbonero R. Longo-Muñoz F, et al. Among authors: gil calle s. Clin Transl Oncol. 2017 Feb;19(2):227-235. doi: 10.1007/s12094-016-1528-7. Epub 2016 Jul 21. Clin Transl Oncol. 2017. PMID: 27443414 Free PMC article. Clinical Trial.
Cisplatin plus continuous infusion vinorelbine for the treatment of advanced non-small cell lung cancer: a phase I-II study.
Cobo-Dols M, Gil-Calle S, Villar-Chamorro E, Alés-Díaz I, Carabantes-Ocón F, Alcalde-García J, Gutiérrez-Calderón V, Montesa-Pino A, Bretón-García JJ, Benavides-Orgaz M. Cobo-Dols M, et al. Among authors: gil calle s. Clin Transl Oncol. 2006 Jul;8(7):519-24. doi: 10.1007/s12094-006-0052-6. Clin Transl Oncol. 2006. PMID: 16870542 Clinical Trial.
Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study.
Carabante-Ocón F, Cobo-Dols M, Benavides-Orgaz M, Gil-Calle S, Alés-Díaz I, Bretón-García JJ, Villar-Chamorro E, Montesa-Pino A, Alcalde-García J, Gutiérrez-Calderón V. Carabante-Ocón F, et al. Among authors: gil calle s. Clin Lung Cancer. 2005 Sep;7(2):121-6. doi: 10.3816/CLC.2005.n.027. Clin Lung Cancer. 2005. PMID: 16179099 Clinical Trial.
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M. Cobo Dols M, et al. Among authors: gil calle s. Clin Transl Oncol. 2006 Oct;8(10):742-9. doi: 10.1007/s12094-006-0121-x. Clin Transl Oncol. 2006. PMID: 17074673 Clinical Trial.
12 results